Critical Outcome Technologies Inc. (COTI)
TSX VENTURE : COT

Critical Outcome Technologies Inc. (COTI)

September 28, 2011 17:19 ET

Critical Outcome Technologies Inc. Announces the Issuance of Stock Options

LONDON, ONTARIO--(Marketwire - Sept. 28, 2011) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that at its Board meeting of September 27, 2011 the Board of Directors approved the granting of 756,098 stock options to its seven Directors under the Company's Stock Option Plan as a retainer for their service on the Board and its committees for the next year. The options have a five year life with 25% vesting at the end of each quarter from the date of grant. The exercise price is $0.30 and represents the closing price of the Company's common shares on September 26, 2011, the last trade reported on the TSX Venture Exchange prior to the meeting date.

"The use of stock options to compensate the board members allows us to conserve our cash, as we move forward with our drug development plans and demonstrates the Directors' belief and commitment to the Company's future," advised Company Chairman, Mr. John Drake.

About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge company specializing in accelerating the discovery of small molecules to enable new drugs to be brought to market in a more cost effective, efficient and timely manner. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds most likely to be successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, please visit our website www.criticaloutcome.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information